uzeronacabtagene autoleucel

Uzeronacabtagene autoleucel is a CD19-directed genetically modified autologous T cell immunotherapy designed for potential use in relapsed or refractory B-cell malignancies. No specific clinical data, approval status, or development details for this exact agent were identified in available sources. It likely employs a chimeric antigen receptor (CAR) targeting CD19 on malignant B cells, leading to T-cell activation, proliferation, and tumor cell killing via the CD3-zeta signaling domain and a 4-1BB costimulatory domain, similar to related CAR-T therapies. Further investigation into developer trials or preclinical data is needed to confirm indications, efficacy, and safety profile.